# Pirouette Pharma (YC S21) Reengineering life-saving injections; #1 most raised campaign in Wefunder history - Canonical URL: https://wefunder.com/pirouette - Entity ID: wefunder:company:141810 - Last updated: 2026-06-03T16:03:34Z - Generated at: 2026-06-03T23:38:23Z ## Quick facts - #1 Wefunder raise in history ($7.8M; 4000+ investors) + backed by top life sciences VCs - $800M+ in licensing deal potential with 4 medications targeting FDA approval in 2027, 2028, and 2029 - Big pharma + an aerospace leader are in advanced talks to use OnePush across multiple medicines - 23 granted patents globally with more pending; clear path to commercialize worldwide by 2027 - 100% of oncologists would prescribe OnePush over current auto-injectors in blinded research study - OnePush targets a $1T dollar injectable market as self‑care shifts to simpler at‑home devices - Type C Meeting with FDA gave a defined path for an OTC approval—a validation of its ease of use! - $600M+ projected in annual sales by year 5 (not guaranteed) ## Active fundraises - wefunder:fundraise:149523: 4(a)(6) successful (USD) - wefunder:fundraise:161061: 506(c) open (USD) - wefunder:fundraise:149522: 4(a)(6) successful (USD) - wefunder:fundraise:134979: 506(c) successful (USD) - wefunder:fundraise:95325: 4(a)(6) successful (USD) - wefunder:fundraise:95324: 4(a)(6) successful (USD) ## Investor memos - Safar Partners: https://uploads.wefunder.com/uploads/remote_files/831622-SbCdhn0WjfMdhoJ8OA0m3wtA/Pirouette_Safar_Partners_Investment_Memo_20240515.pdf - Kingscrowd Capital: https://kingscrowd.com/pirouette-medical-on-wefunder-2024/ ## Story Earlier this year, this community raised $7.8 million on Wefunder—the most funded campaign in the platform's history—proving how powerful mission‑driven capital can be when aligned with patient impact. Demand exceeded our allocation, so before our next institutional raise, we're reopening a final window for our community to join the next phase of growth.​The Problem: Injections at Home Are BrokenPatients are stuck with outdated devices where visible needles trigger fear, leading to delayed treatment, errors, and poor adherence—driving them back to clinics and increasing costs. We're changing that. Instead of forcing life to adapt to treatment, our hidden-needle design makes care simple, consistent, and fear-free.​Our Solution: OnePush™OnePush is our patented, disc‑shaped push-button auto‑injector designed for real life—drug‑agnostic, partner‑ready, and engineered to turn chronic therapies into a preferred patient experience at scale.​Hidden‑Needle Comfort: Fully automatic—the needle is designed to stay invisible before, during, and after injection, with smooth insertion engineered to reduce sensation and prevent anxiety.​Battlefield‑Grade Engineering: ISO‑aligned, rugged performance aiming for first‑try success in any environment.​Made in America: Scaling automated U.S. manufacturing for speed, quality, and confidence.​The OpportunitySterile injectable delivery is a trillion-dollar global market by 2029. We're positioning OnePush to capture a meaningful share of the $150‑billion GLP‑1 class—including Wegovy®, Ozempic®, and Zepbound®—by pairing blockbuster therapies with device‑driven adherence and potential retail access for millions.​Since Our Last Wefunder Raise, We've ExecutedValidated U.S. manufacturing, increased our global patent count to 23 granted, completed a successful FDA Type C meeting supporting over‑the‑counter potential, and built a pipeline with $800M+ in near‑term licensing opportunities.​Join UsWe invite you to be part of this next chapter: scaling automated manufacturing, advancing FDA submissions, and commercializing OnePush to put best‑in‑class self‑injection in the hands of millions.Here's to transforming healthcare, together.ConorFounder & CEO, PirouetteMost patients are still self‑injecting with decades‑old pens and prefilled syringes that force them to stare at exposed needles, manage multiple preparation steps, and hope they did everything correctly. These experiences fuel anxiety, fear, and second‑guessing, and too often lead to delayed doses, avoidable errors, and people quietly abandoning treatment at home.Needle fear affects over 50% of patients, causing hesitation and poor adherence.Most devices rely on bulky, plastic-wrapped syringes or outdated auto-injectors that expose the needle, require high force, and weren’t designed with patients in mind.Even when home use is possible, most injectable medications are still delivered in clinics or pharmacies. Even a routine post-chemotherapy injection can mean driving back to the hospital and home again all for a single shot.Our patented OnePush™ auto-injector platform simplifies the delivery of all injectable drugs.With the global injectable medicine market rapidly expanding to nearly $1T, Pirouette’s OnePush auto-injector is designed to improve brand differentiation and adoption by delivering a more patient‑preferred injection experience. Pirouette’s hidden‑needle comfort for home use reduces needle visibility and sensation, helping patients start and stay on essential medications. This leads to both preference and brand loyalty while supporting better long‑term outcomes and quality of life.With a fully automatic, hidden needle engineered to reduce needle sensation and ease self‑injection anxiety, it strengthens comfort and consistency across a wide range of therapies – from weekly GLP-1s for diabetes and obesity to oncology therapies and HIV medications, as well as hormone injections for IVF.Pirouette is advancing on every front with global patent protection, U.S. manufacturing already online, fully automated high‑through put capacity in development for build‑out in 2026, and a defined regulatory path that keeps us on track for a first FDA approval in under two years and a second within three. We’re primed to scale and commercialize across priority programs.We own the IP and have Freedom to Operate ClearancePirouette’s competitive advantage is backed by one of the strongest intellectual property positions in the industry. We engaged one of the world’s top intellectual property law firms to conduct a rigorous global patent landscape search. Their conclusion: no other company’s patents stand in our way.This gives us an unprecedented legal “green light” to manufacture and sell our flagship OnePush™ auto-injector worldwide, without fear of infringing on others or being blocked by competitor lawsuits. This level of clarity is incredibly rare in medtech, and it’s a major moat for Pirouette.We also fully own the manufacturing IP: every step of the device assembly process, inspection protocol, and production tooling is protected and proprietary. This means we can build, scale, and ship on our own terms—without relying on third parties or risking production disruption. No one else can manufacture OnePush without us.First, we partner with big pharmaceutical companies. They bring us their blockbuster medicines—drugs that are already proven and approved—and we package them into OnePush. These partnerships generate upfront payments, development milestones, and ongoing royalties every time a dose is sold, creating a steady revenue stream without Pirouette having to sell the drugs ourselves.Second, we bring our own medicines to market. We take proven, well-established injectable drugs that are losing or have lost patent protection—including blockbuster GLP-1 therapies like semaglutide (the active ingredient in Wegovy® and Ozempic®) and dulaglutide (Trulicity®)—and pair them with OnePush using streamlined FDA pathways called 505(b)(2) and 351(k).These pathways let us rely on existing safety and effectiveness data for the drug itself, so we only need to run studies proving our device delivers the dose correctly and that patients can use it easily at home. When we launch these products under our own brand, Pirouette captures the full revenue and profit margin—not just royalties.​Together, these two models give us multiple shots on goal: steady partnership income and the potential for high-margin product sales as we scale.Disclaimer: Certain information set forth on this page contains "forward-looking information", including "future-oriented financial information" and "financial outlook", under applicable securities laws. These are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking information necessarily involves known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance. All investments involve risk, including the potential loss of capital. Pirouette’s products presented are not approved by regulatory authorities in any markets and the statements in this presentation represent design intent and are not product claims. ## FAQ 1. **How do investors at this stage get a ROI? What are the trigger events to convert investment money into shares later on?** - Great question! You can learn more about the ROI here: https://help.wefunder.com/#/investor/after-you-invest The triggering event for the SAFE to convert to shares is the next "Qualified Financing" as described here: "In the event that the Company issues and sells Preferred Stock in a bona fide transaction or series of transactions with the principal purpose of raising capital for aggregate proceeds of at least US$10,000,000 at a fixed valuation, including but not limited to, a pre-money or p... 2. **Conor, Few questions. 1. Regarding the narcan, your competition would be not just from other autoinjection products but intranasal products. Even if your autojectable narcan is the best and cheapest on the market how do you compete against intranasal narcan and did any of your...** - Hi David - these are all great questions! “I lost a couple nephews and a niece, and I'm convinced a device like this could have saved them.” -Opioid Dependent User “I absolutely loved the device. The stick function [adhesive base] is great. What you pointed out about nasal sprays, how patient orientation matters, you’ve done a lot of research, I didn’t even think about that and how the drug can dribble down the patient’s face.” -Legislative Assistant (Healthcare) at the U.S. House of Represen... 3. **Are they recyclable maybe even re-usable? Or just one time use and trash? Sorry if you already put that info in the info and I missed it.** - Hi Mical, thanks for the question! At this time the devices are based off of our first generation auto-injector platform and are single-use, disposable systems. The single-use nature aims to make the device intuitive to use and reduce complexity. In the future, we foresee a potential for a next generation version that could be multi-use. 4. **Hello Conor, I made an investment, but considering upping it depending upon what I learn from the answers to my questions. - Is there a standard for vial that you are building the platform to? size/format etc. - If yes, what is the friction in introducing new drugs with your p...** - Hi Prakash, thanks for the fantastic questions. The short answer is YES! We use the pharma standards as much as possible to make it simple for partners to pair their drug with our device. The container closure system is a standard type I glass of common ID/OD, and sits in a standard nest/tub configuration for compatibility with the standard fill/finish process. We can operate either way, receiving the drug product and completing all kitting or licensing the device to the partner if they want ... 5. **What is the price of each share of Pirouette Medical Devices on wefunder.com!@** - Hello! The vehicle is a SAFE which converts to equity at the next priced round. Check out https://help.wefunder.com/#/glossary/contract for more information. ## Team - Conor R. Cullinane, Ph.D. (President & CEO) - Elijah Kapas (CTO) - Matthew Kane (COO) - Kevin Statz (Chief Commercial Officer) - Erin Beauregard (Chief of Staff) - Phil Littlefield (VP of Supply Chain) - Emily Deane (VP of Quality) - Thomas J. Hook (Lead Investor) - Joe Nemmers (Director & Board Member) - Surbhi Sarna (Investor & Advisor) - Parinaz Motemedy (Investor, Board Member) ## Q&A - Q: Conor, Few questions. 1. Regarding the narcan, your competition would be not just from other autoinjection products but intranasal products. Even if your autojectable narcan is the best and cheapest on the market how do you compete against intranasal narcan and did any of your internal studies elicit patient opinion choosing between an intranasal product and your product? 2. Have you secured any letters of intent or had substantive discussions with any municipalities/health care associations or EMS systems that provide narcan products at a large volume. Any indication they would make a change from their existing product to your product. I know you previously said your revenue projections are based on other companies market share gains when they entered the market, but I am curious to know if large scale entities have indicated a desire to change to your product (rather than a vague response in a survey)? 3. Regarding epinephrine. I would imagine EMS would be a large, low hanging fruit customer as epi is a high error/risk medication (often mixed up for other drugs or dosed incorrectly). Any conversations with EMS systems about willingness to use your product. 4. Can you comment on the parts to your 55M valuation cap. Revenue isn't projected to start for another 4 years (2028). This revenue projection is based on other companies market share on entrance, but as you know the market is pretty well saturated with injectables. From your prior statements it sounds like you plan on taking share through a more intuitive and cheaper product. However, what would keep a competitor from lowering prices to avoid share loss? And a more intuitive product is only helpful if it can overcome switching costs (hassle of making a change) and the status quo bias. Thanks in advance for answering these questions. David - A: Hi David - these are all great questions! “I lost a couple nephews and a niece, and I'm convinced a device like this could have saved them.” -Opioid Dependent User “I absolutely loved the device. The stick function [adhesive base] is great. What you pointed out about nasal sprays, how patient orientation matters, you’ve done a lot of research, I didn’t even think about that and how the drug can dribble down the patient’s face.” -Legislative Assistant (Healthcare) at the U.S. House of Representatives “I really like the adhesive characteristic, portability and sharps mitigation of the Naloxone Auto-Injector.” -State Law Enforcement Agent and Paramedic 1. You are absolutely right, we will be directly competing with a nasal spray in the Naloxone market. While intranasal Narcan is a useful weapon in the war on opioid overdose, studies indicate that intramuscular (IM) Naloxone is over 2x more effective than intranasal, offering better absorption and requiring fewer follow-up doses. This is crucial against powerful opioids like fentanyl. Our autoinjector is especially suited for rural areas hardest hit by the opioid crisis. Our recent survey of 90 opioid-dependent users and healthcare professionals (HCPs) at a New England treatment facility highlighted the Naloxone Auto-Injector's advantages over nasal sprays. Users reported instances where nasal sprays failed to deliver effective doses due to poor atomization, especially in confined spaces such as bathrooms or when the patient was seated (i.e. in cars), leading to critical delays in treatment. One participant noted the ineffectiveness of two nasal doses, with revival only after a more invasive third dose. In contrast, the auto-injector is aimed at ensuring rapid, full dosing. Tragically, one respondent attributed the loss of several family members to the inadequacy of nasal Naloxone, “I lost a couple nephews and a niece, and I'm convinced a device like this could have saved them.” We’re continuing to engage all stakeholders in the next several months, through the NIH/NIDA I-Corps program. We will expand our research by visiting clinics nationwide to gather more insights from those on the opioid crisis frontline. 2. Yes, we’ve engaged in multiple discussions with EMTs, paramedics, and nursing personnel across the eastern seaboard who have collectively treated over 4000 opioid overdose events. We’ve also talked to law enforcement and fire department personnel that often carry counter-opioid devices through various harm reduction programs. There's significant interest in replacing intranasal opioid reversal agents with Pirouette’s auto-injector, notably for its usability and dose confirmation feature. One Law Enforcement Officer and paramedic praised the Naloxone Auto-Injector’s improved usability over intranasal devices. He recounted that unlike the Naloxone Auto-Injector, most if not all intranasal devices lack delivered dose confirmation mechanisms with patients being administered up to 20mg of Naloxone – five times the initial dosing parameters due to improper administration technique. He’d love to propose the Naloxone Auto-Injector as a replacement. Since many of these programs are state or federally subsidized, a low Cost of Goods Sold (COGS) is critical to that transition. Pirouette incorporated this into the design, material selection, and manufacturability process, to give us an edge as we aim to be the first, truly low-cost auto-injector that is competitively priced. Pirouette has also connected with key decision and policy makers such as Congresswoman Kuster’s office (NH-02) and Congressman Pappas’ office (NH-01) who have been instrumental in opioid treatment policy reform and expanding government funding programs through the SUPPORT Act. We’ve received pledges of support and are continuing to meet with legislative healthcare reps. 3. We raised the same question with EMTs and Paramedics because treatment protocols vary regionally. Of the personnel we talked to, they prefer intramuscular over intranasal administration. The standard protocol is to draw Naloxone from a vial and administer it with a syringe. This is the most cost-effective method and allows them to titrate doses – something single-use auto-injectors aren’t designed to do. As experienced emergency personnel, they are trained to do this in high-stress, time-sensitive situations. Our Naloxone Auto-Injector therefore, might offer significant value for EMS, local law enforcement, and fire departments, especially in distributing "take-home kits" for opioid overdose through local, state, federal, and non-profit programs. Pirouette will target this distribution channel, working with municipal and harm reduction non-profits. In addition, Pirouette is exploring pilot programs with law enforcement, often first on the scene in these situations, to include our auto-injector in their kit. Its durability, compactness, and ease of use are aimed to make it an ideal replacement for their current devices, enhancing safety and response efficiency without requiring medical expertise. 4. The $55M Cap is used to calculate the price per share when the SAFE converts in the next priced round (Series B). Price per share is calculated using the 20% discount and using the $55M Cap - whichever gives a better (lower) price is what is used. This structure ensures a minimum 20% discount, potentially more, depending on Series B's pre-money valuation, incentivizing early investors to enhance company value. We are forecasting the Series B for 2026, coinciding with anticipated FDA approval in 2026 and commercialization in 2027. A few items that /drive our valuation are: A. A stellar management team with over a decade of experience working together and the expertise to execute this solution. The company’s core competencies bridge advanced engineering principles, a mastery of extreme reliability, complex and highly regulated development, and medical devices/pharmaceuticals. These core competencies are built on the founding team, the experts surrounding the management team, and the employees, in addition to industry-leading consultants wherever needed, such as regulatory. B. The management team is surrounded by industry titans and boasts an extensive network of investors and advisors who provide continued support and expertise.. The ability to rely on seasoned veterans who have walked our path and been on every side of the table at some point allows Pirouette to move rapidly and avoid pitfalls that would otherwise plague small companies in this space. https://youtu.be/oI4vrg8Y68w C. A pipeline in a product! Development efforts have been strategically focused on the platform technology that could be paired with many injectable medications - a huge, growing market opportunity. Innovative solution, while maintaining the necessary pharma industry standards for critical processes including formulation/fill/finish of the injectable medications. This means an easy adoption for pharma partners who want to pair their drugs with our solution for a unique competitive advantage. D. Ownership of the entire supply chain. E. In-house manufacturing capabilities (10,000 sqft manufacturing space and a 1,000 sqft ISO Class 8 Cleanroom). Our investment in manufacturing directly supports any medication pairings, accelerating the pathway to rapidly expanding to new markets. F. Support from the NIH and NIDA for our Naloxone Auto-Injector through non-dilutive funding (Phase I awarded, Phase II applied) and commercialization preparation (I-Corps Program). We are also serving as a research site for NIH’s summer internship program where interns, paid by the NIH, will be onsite and contribute to our efforts towards FDA approval. G. Testing in-house. We have significantly invested in testing equipment and infrastructure to accomplish required design verification, design validation, in-process testing, and batch release testing on-site. This infrastructure will support our flagship products and future medication pairings to come. H. Strong IP. 18 Issued utility patents, 7 more pending. I. Strong adoption potential with an innovative device at an affordable price. - Q: Conor: I love the concept! I do have a question: I am a physician who has had to administer epinephrine for anaphyactic reactions on more than one occasion. (I am a radiologist, and every so often a patient will have a severe reaction to administered IV contrast. Thus we have to be prepared to administer the appropriate medication with very little warning.) Right now, our clinics stock the Auvi-Q epinephrine autoinjector as part of our standard "drug kit". Part of the reason we selected Auvi-Q is because our staff find their device to be user friendly and much less intimidating than EpiPens in an urgent scenario. Can you lay out some of the pros and cons of the QuicPush vs. the Auvi-Q? More broadly, what are some of the key distinctions between the Pirouette device and other competitors who are also attempting to create a more user-friendly device? If QuicPush works as expected, I can easily see it becoming a standard part of our drug boxes. Thanks for any thoughts you are willing to share. - A: Hi Paul - great questions and I appreciate the vote of confidence. For our technology our focus has been driving the key differentiation through a better device at an affordable price. We are aiming to make our device so intuitive and easy to use that it can be picked up and used correctly the first time by individuals with limited or no training. - Q: Hi Pirouette Team, I'm Zac from D3VC, and we focus on prime opportunities within equity crowdfunding. Your project caught our attention, but I've got a couple of questions: -Considering the importance of affordability in patient access to life-saving medication, how does Pirouette plan to position its product price-wise? Are there strategies to work with insurance companies to ensure broad coverage? -Given the competitive landscape, what concrete evidence or feedback do you have that showcases a preference for Pirouette's delivery system over traditional methods? Specifically, how does this feedback translate into your go-to-market strategy? Looking forward to your insights. Thanks! - A: Hi Zac, great questions and we would love to have D3VC onboard. We plan to price our products as competitively as we can. We have always said, "A better device at an affordable price". More on the pricing and reimbursement strategy was discussed in our latest webinar: https://us02web.zoom.us/rec/share/Cgk5NCa4VxFeONYtzfEyX9XQgO7KdAgEENHnoAH1WwLPcdlLBVsu4nziIXaBYnJ_.qjeBBPzsgFB7BL2W?startTime=1712764859000 For evidence of potential adoption, we completed a survey of 918 epinephrine auto-injector patients and 258 prescribing physicians. 93% of patients and 70% of prescribers wanted to switch to QuicPush. The GTM strategy is built on value propositions for each stakeholder such as the patients and prescribers, and data that we have collected through interactions with each has informed that plan. Additionally, our participation in the NIH I-Corps program is specifically geared towards further developing our GTM strategy based on interactions with all key stakeholders. Looking forward to having you onboard. - Q: I'm not sure this is still being monitored, but I'm curious if Pirouette is working with any of the weight loss pharmaceuticals to adopt Pirouette's injection products? I think these companies would love an injection device for their drugs that is not as scary as the injection methods they are selling now. - Q: How does this compare to an auvi q? - A: Auviq has audible instructions and is rectangular, with its largest dimension perpendicular to the injection site at the moment of an injection. Pirouette's push button injector was designed from the beginning to be so simple and intuitive that it wouldn't need audible instructions, which can save on the cost and complexity. Additionally, Pirouette's push button injector's largest dimension is in parallel to the injection site at the moment of injection which is designed to provide an extremely stable and unintimidating experience for the patient and end user. Pirouette's wide base is also covered with an adhesive, aiming to support the simple easy to use nature. - Q: how to invest? - A: wefunder.com/pirouette/invest - Q: How do I invest - A: wefunder.com/pirouette/invest - Q: Can I still invest in Pirouette Pharma if an opening arises> Steffi Weryzynski (itsmesteffi@hotmail.com) - A: wefunder.com/pirouette/invest - Q: I see my investment funded but the round has not closed yet? I submitted accreditation information and would like to confirm status. Thanks - A: I am able to see the investment on my end it is in the "ready" status, so you are all set. It should be pulled in the coming weeks. - Q: how do I get back to the accredited investor page for this deal? - A: This should now work if you are logged into your Wefunder account: https://wefunder.com/pirouette. - Q: as a reg D investor when will we receive our investment documents. Thank you. - A: Once you complete your investment, you will be able to see all of the documentation at wefunder.com/portfolio. - Q: How can I get information to wire funds from my bank account? - A: If you go to https://wefunder.com/pirouette/wire_info, you will be able to view the wire instructions. But note that wire transfers are only available for investments of $1,000 or more. For investments less than that amount, you can invest via bank transfer (ACH) or credit card. - Q: Where is the Reg CF offering at? - A: Go to https://wefunder.com/pirouette/invest and then you can select the "Go to Reg CF" button. If you don't see it let me know! - Q: how can i access FORM C please - A: Pirouette's most recent Form C filing can be found on the SEC's portal here: https://www.sec.gov/edgar/browse/?CIK=1870611 - Q: This looks like a terrific opportunity and an important advance. One of my biggest complaints about investing in crowd opportunities is that often management never communicates with investors and you have no idea if the company is even still in business. What is your plan to keep investors informed of the company's progress? Thank you. - A: I release a monthly investor update. Something we are very proud of is we have a significant proportion of investors that invest multiple times and part of that is a testament to open and frequent communication.